Oatp58Dc contributes to blood-brain barrier function by excluding organic anions from the Drosophila brain

American Journal of Physiology - Cell Physiology

Volumn 305, Issue 5, 2013, Pages

  Seabrooke, Sara ^a   O'Donnell, Michael J ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Drosophila; Fluorescein; Organic anion transporting polypeptide; Perineurial; Subperineurial

Indexed keywords

FLUORESCEIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTING POLYPEPTIDE 58DC PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANION TRANSPORT; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DROSOPHILA; GENETIC MANIPULATION; GLIA CELL; HEMOLYMPH; IMMUNOCYTOCHEMISTRY; MICROINJECTION; MOLECULAR DYNAMICS; NERVE CELL; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

DROSOPHILA; FLUORESCEIN; ORGANIC ANION-TRANSPORTING POLYPEPTIDE; PERINEURIAL; SUBPERINEURIAL;

AMINO ACID SEQUENCE; ANIMALS; ANIONS; BLOOD-BRAIN BARRIER; BRAIN; DROSOPHILA MELANOGASTER; DROSOPHILA PROTEINS; FLUORESCEIN; FLUORESCENT DYES; GENE EXPRESSION REGULATION; HEMOLYMPH; ION TRANSPORT; MOLECULAR SEQUENCE DATA; NEUROGLIA; NEURONS; ORGANIC ANION TRANSPORTERS;

EID: 84883440422     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00408.2012     Document Type: Article

References (60)

1. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev 7: 41-53, 2006.
2. Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J, Ahuja A, Akbar M. Strategy for effective brain drug delivery. Eur J Pharm Sci 40: 385-403, 2010.
3. Amsterdam JD, Shults J. Does tachyphylaxis occur after repeated antidepressant exposure in patients with bipolar II major depressive episode? J Affect Disord 115: 234-240, 2009.
4. Amsterdam JD, Williams D, Michelson D, Adler LA, Dunner DL, Nierenberg AA, Reimherr FW, Schatzberg AF. Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. Neuropsychobiology 59: 227-233, 2009.
5. Awasaki T, Lai SL, Ito K, Lee T. Organization and postembryonic development of glial cells in the adult central brain of Drosophila. J Neurosci 28: 13742-13753, 2008.
6. Bainton RJ, Tsai LT, Schwabe T, DeSalvo M, Gaul U, Heberlein U. moody encodes two GPCRs that regulate cocaine behaviors and bloodbrain barrier permeability in Drosophila. Cell 123: 145-156, 2005.
7. Billinton N, Knight AW. Seeing the wood through the trees: a review of techniques for distinguishing green fluorescent protein from endogenous autofluorescence. Anal Biochem 291: 175-197, 2001.
8. Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118: 401-415, 1993.
9. Bresler SE, Bresler VM, Kazbekov EN, Nikiforov AA, Vasilieva NN. On the active transport of organic acids (fluorescein) in the choroid plexus of the rabbit. Biochim Biophys Acta 550: 110-119, 1979.
10. Chahine S, Campos A, O'Donnell MJ. Genetic knockdown of a single organic anion transporter alters the expression of functionally related genes in Malpighian tubules of Drosophila melanogaster. J Exp Biol 215: 2601-2610, 2012.
11. Chahine S, O'Donnell MJ. Effects of acute or chronic exposure to dietary organic anions on secretion of methotrexate and salicylate by Malpighian tubules of Drosophila melanogaster larvae. Arch Insect Biochem Physiol 73: 128-147, 2010.
12. Chahine S, Seabrooke S, O'Donnell MJ. Effects of genetic knock-down of organic anion transporter genes on secretion of fluorescent organic ions by Malpighian tubules of Drosophila melanogaster. Arch Insect Biochem Physiol 81: 228-240, 2012.
13. Daneman R, Zhou L, Agalliu D, Cahoy JD, Kaushal A, Barres BA. The mouse blood-brain barrier transcriptome: a new resource for understanding the development and function of brain endothelial cells. PLos One 5: e13741, 2010.
14. De Bruyn T, Fattah S, Stieger B, Augustijns P, Annaert P. Sodium fluorescein is a probe substrate for hepatic drug transport mediated by OATP1B1 and OATP1B3. J Pharm Sci 100: 5018-5030, 2011.
15. DeSalvo MK, Mayer N, Mayer F, Bainton RJ. Physiologic and anatomic characterization of the brain surface glia barrier of Drosophila. Glia 59: 1322-1340, 2011.
16. Dietzl G, Chen D, Schnorrer F, Su KC, Barinova Y, Fellner M, Gasser B, Kinsey K, Oppel S, Scheiblauer S, Couto A, Marra V, Keleman K, Dickson BJ. A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 448: 151-156, 2007.
17. Fagerholm U. The highly permeable blood-brain barrier: an evaluation of current opinions about brain uptake capacity. Drug Discov Today 12: 1076-1082, 2007.
18. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 294: 73-79, 2000.
19. Gao B, Stieger B, Noe B, Fritschy JM, Meier PJ. Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47: 1255-1264, 1999.
20. Girardin F. Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin Neurosci 8: 311-321, 2006.
21. Golden PL, Pollack GM. Blood-brain barrier efflux transport. J Pharm Sci 92: 1739-1753, 2003.
22. Gui C, Obaidat A, Chaguturu R, Hagenbuch B. Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics 4: 1-8, 2010.
23. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflügers Arch 447: 653-665, 2004.
24. Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609: 1-18, 2003.
25. Hamby SE, Hirst JD. Prediction of glycosylation sites using random forests. BMC Bioinformatics 9: 500, 2008.
26. Hanggi E, Grundschober AF, Leuthold S, Meier PJ, St-Pierre MV. Functional analysis of the extracellular cysteine residues in the human organic anion transporting polypeptide, OATP2B1. Mol Pharmacol 70: 806-817, 2006.
27. Hargittai PT, Butt AM, Lieberman EM. High potassium selective permeability and extracellular ion regulation in the glial perineurium (blood-brain barrier) of the crayfish. Neuroscience 38: 163-173, 1990.
28. Hawkins BT, Egleton RD. Fluorescence imaging of blood-brain barrier disruption. J Neurosci Methods 151: 262-267, 2006.
29. Hawkins BT, Ocheltree SM, Norwood KM, Egleton RD. Decreased blood-brain barrier permeability to fluorescein in streptozotocin-treated rats. Neurosci Lett 411: 1-5, 2007.
30. Hawkins RA, Peterson DR, Vina JR. The complementary membranes forming the blood-brain barrier. IUBMB Life 54: 101-107, 2002.
31. Kusuhara H, Sugiyama Y. Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2: 73-85, 2005.
32. Leader JP, O'Donnell MJ. Transepithelial transport of fluorescent p-glycoprotein and MRP2 substrates by insect Malpighian tubules: confocal microscopic analysis of secreted fluid droplets. J Exp Biol 208: 4363-4376, 2005.
33. Li JY, Boado RJ, Pardridge WM. Blood-brain barrier genomics. J Cereb Blood Flow Metab 21: 61-68, 2001.
34. Linton SM, O'Donnell MJ. Novel aspects of the transport of organic anions by the Malpighian tubules of Drosophila melanogaster. J Exp Biol 203: 3575-3584, 2000.
35. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev 6: 591-602, 2005.
36. Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76: 22-76, 2005.
37. Mayer F, Mayer N, Chinn L, Pinsonneault RL, Kroetz D, Bainton RJ. Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in Drosophila. J Neurosci 29: 3538-3550, 2009.
38. Meier-Abt F, Mokrab Y, Mizuguchi K. Organic anion transporting polypeptides of the OATP/SLCO superfamily: identification of new members in nonmammalian species, comparative modeling and a potential transport mode. J Membr Biol 208: 213-227, 2005.
39. Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 31: 246-254, 2010.
40. Mori S, Ohtsuki S, Takanaga H, Kikkawa T, Kang YS, Terasaki T. Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem 90: 931-941, 2004.
41. Mulenga A, Khumthong R, Chalaire KC, Strey O, Teel P. Molecular and biological characterization of the Amblyomma americanum organic anion transporter polypeptide. J Exp Biol 211: 3401-3408, 2008.
42. Neuwelt E, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T, Engelhardt B, Grammas P, Nedergaard M, Nutt J, Pardridge W, Rosenberg GA, Smith Q, Drewes LR. Strategies to advance translational research into brain barriers. Lancet Neurol 7: 84-96, 2008.
43. Ohtsuki S, Takizawa T, Takanaga H, Hori S, Hosoya K, Terasaki T. Localization of organic anion transporting polypeptide 3 (oatp3) in mouse brain parenchymal and capillary endothelial cells. J Neurochem 90: 743-749, 2004.
44. Pinsonneault RL, Mayer N, Mayer F, Tegegn N, Bainton RJ. Novel models for studying the blood-brain and blood-eye barriers in Drosophila. Methods Mol Biol 686: 357-369, 2011.
45. Redzic ZB, Biringer J, Barnes K, Baldwin SA, Al-Sarraf H, Nicola PA, Young JD, Cass CE, Barrand MA, Hladky SB. Polarized distribution of nucleoside transporters in rat brain endothelial and choroid plexus epithelial cells. J Neurochem 94: 1420-1426, 2005.
46. Ruiz-Sanchez E, O'Donnell MJ. Effects of chronic exposure to dietary salicylate on elimination and renal excretion of salicylate by Drosophila melanogaster larvae. J Exp Biol 210: 2464-2471, 2007.
47. Schwabe T, Bainton RJ, Fetter RD, Heberlein U, Gaul U. GPCR signaling is required for blood-brain barrier formation in Drosophila. Cell 123: 133-144, 2005.
48. Seabrooke S, Stewart BA. Moesin helps to restrain synaptic growth at the Drosophila neuromuscular junction. Dev Neurobiol 68: 379-391, 2008.
49. Steuer H, Jaworski A, Elger B, Kaussmann M, Keldenich J, Schneider H, Stoll D, Schlosshauer B. Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier. Invest Ophthalmol Vis Sci 46: 1047-1053, 2005.
50. Stork T, Bernardos R, Freeman MR. Analysis of glial cell development and function in Drosophila. Cold Spring Harbor Protoc 2012: 1-17, 2012.
51. Stork T, Engelen D, Krudewig A, Silies M, Bainton RJ, Klambt C. Organization and function of the blood-brain barrier in Drosophila. J Neurosci 28: 587-597, 2008.
52. Su Y, Sinko PJ. Drug delivery across the blood-brain barrier: why is it difficult? How to measure and improve it? Expert Opin Drug Deliv 3: 419-435, 2006.
53. Sugiyama D, Kusuhara H, Taniguchi H, Ishikawa S, Nozaki Y, Aburatani H, Sugiyama Y. Functional characterization of rat brainspecific organic anion transporter (Oatp14) at the blood-brain barrier: high affinity transporter for thyroxine. J Biol Chem 278: 43489-43495, 2003.
54. Sun H, Dai H, Shaik N, Elmquist WF. Drug efflux transporters in the CNS. Adv Drug Deliv Rev 55: 83-105, 2003.
55. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273: 251-260, 2000.
56. Tohyama K, Kusuhara H, Sugiyama Y. Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. Endocrinology 145: 4384-4391, 2004.
57. Torrie LS, Radford JC, Southall TD, Kean L, Dinsmore AJ, Davies SA, Dow JA. Resolution of the insect ouabain paradox. Proc Natl Acad Sci USA 101: 13689-13693, 2004.
58. Urquhart BL, Kim RB. Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 65: 1063-1070, 2009.
59. Wu JS, Luo L. A protocol for dissecting Drosophila melanogaster brains for live imaging or immunostaining. Nat Protoc 1: 2110-2115, 2006.
60. Zimmerman M, Thongy T. How often do SSRIs and other newgeneration antidepressants lose their effect during continuation treatment? Evidence suggesting the rate of true tachyphylaxis during continuation treatment is low. J Clin Psychiatry 68: 1271-1276, 2007.